BMS201038

01/01/2020 - "Recently, in Europe, to evaluate the long-term safety and efficacy of lomitapide, the LOWER registry (ClinicalTrials.gov Identifier: NCT02135705) has been established in order to acquire informations on HoFH lomitapidetreated patients from "real life" clinical practice. "
04/01/2019 - "Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study."
11/01/2020 - "Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)."
01/01/2022 - "This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe. "
01/01/2020 - "Data from case series of varying sizes, and from a 163-patient registry of HoFH patients receiving lomitapide, have demonstrated that lomitapide doses are lower and adverse events less severe than in the phase 3 study. "

10/01/2022 - "The open-label, single-arm 'LOCHNES' study of lomitapide in FCS enrolled patients >18 years with genetically confirmed FCS, elevated fasting TG ≥ 750 mg/dL and history of pancreatitis. "
10/01/2022 - "Lomitapide is effective and well tolerated in reducing TGs in FCS patients with a history of pancreatitis. "
01/01/2021 - "We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. "
10/01/2022 - "No patient experienced acute pancreatitis or severe abdominal pain during lomitapide treatment. "
03/01/2014 - "Lomitapide prevented pancreatitis in severe intractable hypertriglyceridemia but at a potential long-term cost of hepatotoxicity."

12/01/2016 - "Lomitapide for the treatment of hypertriglyceridemia."
03/01/2014 - "Lomitapide prevented pancreatitis in severe intractable hypertriglyceridemia but at a potential long-term cost of hepatotoxicity."
03/01/2014 - "Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide."
12/01/2016 - "Areas covered: Published trials of lomitapide that reported plasma triglyceride response were reviewed, as was a case report of a patient with hypertriglyceridemia who was treated for 13 years with lomitapide. "
05/01/2011 - "2. The in vivo activity of BMS-201038, a potent inhibitor of MTP, was evaluated in a model of hypertriglyceridemia induced by Triton WR1339 and corn oil in Zucker fatty rats. "

01/01/2022 - "Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study."

01/01/2018 - "Within 1 year of screening, from a population of 3250 patients admitted to our cardiology department, seven probands were selected with a DLCN score greater than 5. A total of two patients resulted genetically homozygotes for familial hypercholesterolemia and started lomitapide. "
10/01/2011 - "An oral formulation of lomitapide is in phase III development for homozygous familial hypercholesterolemia (hyperlipoproteinemia type IIa) in the US, Canada, Italy, and South Africa. "
01/01/2022 - "Lomitapide, a microsomal triglyceride transfer protein inhibitor, is approved to treat familial hypercholesterolemia, associated with liver fat accumulation. "
07/01/2015 - "Mipomersen and lomitapide have been approved for use in patients with familial hypercholesterolemia, a more common disease than appreciated. "
10/01/2013 - "Lomitapide and mipomersen are two new pharmacologic options for treatment of familial hypercholesterolemia. "